Source comparison
BPC-157 vs Prolotherapy Joint Tendon Repair: Full Comparison
Mechanism Direct VEGF upregulation and fibroblast activation. Promotes angiogenesis and collagen synthesis without requiring inflammation Controlled inflammatory trigger using dextrose or PRP. Restarts stalled repair cascade through macrophage and fibroblast r
This comparison does not assign a generated winner or score.
- Mechanism
- Direct VEGF upregulation and fibroblast activation. Promotes angiogenesis and collagen synthesis without requiring inflammation
- Controlled inflammatory trigger using dextrose or PRP. Restarts stalled repair cascade through macrophage and fibroblast recruitment
- BPC-157 bypasses inflammation; prolotherapy depends on it
- Ideal Injury Phase
- Acute to subacute (0–6 weeks post-injury)
- Chronic (>12 weeks post-injury with stalled healing)
- BPC-157 works when tissue is trying to heal but lacks resources; prolotherapy works when healing has stopped
- Administration
- Subcutaneous or intramuscular injection, systemic circulation
- Direct injection into damaged ligament, tendon, or joint capsule
- BPC-157 doesn't require anatomical precision; prolotherapy must be injected at the exact injury site
- Dosing Protocol
- 200–500 mcg daily, 4–8 week cycles
- 3–6 injection sessions spaced 4–6 weeks apart
- BPC-157 is daily self-administration; prolotherapy is periodic in-office procedure
- Regulatory Status
- Investigational research peptide, no FDA approval
- Off-label use of FDA-approved dextrose, accepted regenerative therapy
- BPC-157 is legally gray; prolotherapy is established but inconsistently covered by insurance
- Evidence Quality
- Animal models with strong mechanistic data, minimal human RCTs
- Moderate clinical evidence from meta-analyses, inconsistent trial methodology
- BPC-157 is preclinical; prolotherapy is clinical but methodologically weak
- Cost per Cycle
- $150–$350 for 4–8 weeks of research-grade peptide
- $300–$600 per injection session, $1,200–$3,600 for full protocol
- BPC-157 is cheaper upfront but requires self-injection; prolotherapy is provider-administered
- Side Effect Profile
- Minimal reported adverse events in animal studies, human data insufficient
- Injection site pain, transient inflammation, rare infection risk
- BPC-157 side effects are unknown; prolotherapy side effects are predictable and manageable
- Response Timeline
- Tissue changes visible at 2–4 weeks in animal models
- Pain reduction at 8–16 weeks, tissue remodeling evidence inconsistent
- BPC-157 may work faster but lacks human confirmation; prolotherapy has delayed onset
- Bottom Line
- Strongest option for early-stage injuries where angiogenesis is rate-limiting. Experimental status is the trade-off
- Proven option for chronic injuries where inflammation has stalled. Requires functional immune response
- BPC-157 for acute repair acceleration; prolotherapy for chronic injury reset